BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 29238934)

  • 1. Treatment outcome of non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae infections: a multicenter study in Taiwan.
    Su CF; Chuang C; Lin YT; Chan YJ; Lin JC; Lu PL; Huang CT; Wang JT; Chuang YC; Siu LK; Fung CP
    Eur J Clin Microbiol Infect Dis; 2018 Apr; 37(4):651-659. PubMed ID: 29238934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical features of patients with carbapenem nonsusceptible Klebsiella pneumoniae and Escherichia coli in intensive care units: a nationwide multicenter study in Taiwan.
    Chang YY; Chuang YC; Siu LK; Wu TL; Lin JC; Lu PL; Wang JT; Wang LS; Lin YT; Huang LJ; Fung CP
    J Microbiol Immunol Infect; 2015 Apr; 48(2):219-25. PubMed ID: 25074627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Outcome of Bacteremia Due to Non-Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy.
    Lee NY; Tsai CS; Syue LS; Chen PL; Li CW; Li MC; Ko WC
    Clin Ther; 2020 Mar; 42(3):e33-e44. PubMed ID: 32061374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of carbapenem resistance on epidemiology and outcomes of nonbacteremic Klebsiella pneumoniae infections.
    Ny P; Nieberg P; Wong-Beringer A
    Am J Infect Control; 2015 Oct; 43(10):1076-80. PubMed ID: 26190386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Klebsiella pneumoniae Infections in the Intensive Care Unit: Risk Factors Related to Carbapenem Resistance and Patient Mortality].
    Büyüktuna SA; Hasbek M; Çelik C; Ünlüsavuran M; Avcı O; Baltacı S; Fırtına Topcu K; Elaldı N
    Mikrobiyol Bul; 2020 Jul; 54(3):378-391. PubMed ID: 32755515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Factors for Carbapenem-resistant
    Wang Z; Qin RR; Huang L; Sun LY
    Chin Med J (Engl); 2018 Jan; 131(1):56-62. PubMed ID: 29271381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Factors for the Development of Colistin Resistance during Colistin Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.
    Huang PH; Chen WY; Chou SH; Wang FD; Lin YT
    Microbiol Spectr; 2022 Jun; 10(3):e0038122. PubMed ID: 35652641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outbreak of carbapenem-resistant Klebsiella pneumoniae in Puerto Rico associated with a novel carbapenemase variant.
    Gregory CJ; Llata E; Stine N; Gould C; Santiago LM; Vazquez GJ; Robledo IE; Srinivasan A; Goering RV; Tomashek KM
    Infect Control Hosp Epidemiol; 2010 May; 31(5):476-84. PubMed ID: 20334553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality.
    Rojas LJ; Salim M; Cober E; Richter SS; Perez F; Salata RA; Kalayjian RC; Watkins RR; Marshall S; Rudin SD; Domitrovic TN; Hujer AM; Hujer KM; Doi Y; Kaye KS; Evans S; Fowler VG; Bonomo RA; van Duin D;
    Clin Infect Dis; 2017 Mar; 64(6):711-718. PubMed ID: 27940944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Retrospective Analysis of Risk Factors and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Nontransplant Patients.
    Xiao T; Zhu Y; Zhang S; Wang Y; Shen P; Zhou Y; Yu X; Xiao Y
    J Infect Dis; 2020 Mar; 221(Suppl 2):S174-S183. PubMed ID: 32176799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections.
    Dubrovskaya Y; Chen TY; Scipione MR; Esaian D; Phillips MS; Papadopoulos J; Mehta SA
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5394-7. PubMed ID: 23959321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Controlling infection and spread of carbapenems-resistant Klebsiella pneumoniae among burn patients].
    Huan J
    Zhonghua Shao Shang Za Zhi; 2015 Feb; 31(1):5-8. PubMed ID: 25876631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbapenem-resistant Klebsiella pneumoniae urinary tract infection following solid organ transplantation.
    Brizendine KD; Richter SS; Cober ED; van Duin D
    Antimicrob Agents Chemother; 2015 Jan; 59(1):553-7. PubMed ID: 25385105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization and predictors of mortality: a retrospective study.
    Jiao Y; Qin Y; Liu J; Li Q; Dong Y; Shang Y; Huang Y; Liu R
    Pathog Glob Health; 2015 Mar; 109(2):68-74. PubMed ID: 25707874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbapenem resistant Klebsiella pneumoniae isolated from bloodstream infection: Indian experience.
    Veeraraghavan B; Shankar C; Karunasree S; Kumari S; Ravi R; Ralph R
    Pathog Glob Health; 2017 Jul; 111(5):240-246. PubMed ID: 28670975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Epidemiology and Risk Factors of Carbapenem-Resistant Klebsiella Pneumoniae Bloodstream Infections in Wuhan, China.
    Liu C; Liu L; Jin MM; Hu YB; Cai X; Wan L; Zhang HY; Li RY; Wu XJ
    Curr Med Sci; 2022 Feb; 42(1):68-76. PubMed ID: 34985611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tigecycline for treatment of carbapenem-resistant Klebsiella pneumoniae infections after liver transplantation in the intensive care unit: a 3-year study.
    Mouloudi E; Massa E; Piperidou M; Papadopoulos S; Iosifidis E; Roilides I; Theodoridou T; Kydona C; Fouzas I; Imvrios G; Papanikolaou V; Gritsi-Gerogianni N
    Transplant Proc; 2014 Nov; 46(9):3219-21. PubMed ID: 25420864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Characterization of Carbapenem-Resistant Enterobacteriaceae and the Spread of Carbapenem-Resistant Klebsiella pneumonia ST340 at a University Hospital in Thailand.
    Netikul T; Kiratisin P
    PLoS One; 2015; 10(9):e0139116. PubMed ID: 26407326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.
    Gomez-Simmonds A; Nelson B; Eiras DP; Loo A; Jenkins SG; Whittier S; Calfee DP; Satlin MJ; Kubin CJ; Furuya EY
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3601-7. PubMed ID: 27044555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae.
    van Duin D; Cober E; Richter SS; Perez F; Kalayjian RC; Salata RA; Evans S; Fowler VG; Kaye KS; Bonomo RA
    J Antimicrob Chemother; 2015 Apr; 70(4):1203-11. PubMed ID: 25492391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.